Alternative therapies for B cell malignancies are urgently needed. We used advances last cycle to develop a new class of recombinant bispecific immunotoxin (IT) with expanded ability to recognize a wider range of B cell cancers. We discovered that this IT could be made by fusing two repeating sFv subunits recognizing human CD19 and human CD22 spliced to truncated DT. This molecule called DT2219 was unique since studies indicated that the hybrid molecule bound better to malignant B cell lines than separate anti-CD19 and anti-CD22 antibodies and was functionally better. DT2219 showed impressive anti-cancer activity against established hematologic human cancer infecting scid mice. The goal of this proposal will be to better define the biology, pharmacology, and toxicology of DT2219 in order to determine whether the sFvs are fully intact, and to determine the manner in which DT2219 is cleared and distributed throughout the body. Also, we will fully define its in vivo anti-tumor activity and toxicity. Despite our encouraging findings and progress, two major problems still exist, toxicity and immunogenicity. Fortunately, because DT2219 is genetically modifiable, we will continue to explore the study of important modifications that we began last cycle. These emphasize reducing toxicity by adding catabolism-inhibiting sequences from Ig constant regions and working on reducing immunogenicity of the sFv region by humanization and reducing the immunogenicity of the toxin by using proapoptotic toxins of human origin.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Welch, Anthony R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
Schools of Medicine
United States
Zip Code
Borgatti, Antonella; Koopmeiners, Joseph S; Sarver, Aaron L et al. (2017) Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR. Mol Cancer Ther 16:956-965
Schmohl, Jörg U; Felices, Martin; Oh, Felix et al. (2017) Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Res Treat 49:1140-1152
Schmohl, J U; Gleason, M K; Dougherty, P R et al. (2016) Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol 11:353-61
Schmohl, Joerg U; Felices, Martin; Todhunter, Deborah et al. (2016) Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker. Oncotarget 7:73830-73844
Schmohl, Joerg U; Felices, Martin; Taras, Elizabeth et al. (2016) Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker. Mol Ther 24:1312-22
Vallera, Daniel A; Felices, Martin; McElmurry, Ron et al. (2016) IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res 22:3440-50
Schmohl, Joerg U; Todhunter, Deborah; Oh, Seung et al. (2015) Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development. Toxins (Basel) 7:4067-82
Bachanova, Veronika; Frankel, Arthur E; Cao, Qing et al. (2015) Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res 21:1267-72
Waldron, Nate N; Barsky, Sanford H; Dougherty, Phillip R et al. (2014) A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma. Target Oncol 9:239-49
Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26

Showing the most recent 10 out of 82 publications